NVTA Stock Recent News
NVTA LATEST HEADLINES
Invitae Corporation (NYSE:NVTA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President & Chief Executive Officer Robert Daber - Chief Scientific Officer Roxi Wen - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Operator Hello, everyone, and welcome to the Invitae First Quarter 2023 Financial Results Conference Call. My name is Emily, and I will be your conference coordinator today.
Invitae grew revenue in 2022 by 12.1%. It had $1.3 billion in net losses last year.
– New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing – SAN FRANCISCO , March 15, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023. The research reinforces the importance of universal genetic testing for patients with cancer, with much of the data highlighting the need for increased representation in clinical genetic testing data across racial, ethnic and ancestry groups that have long been underrepresented in genetic studies and databases.
Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to address its convertible debt deal, fully repaid its senior secured term loan, and reduced its ongoing cash burn to $77 million for the quarter.
Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Invitae Corporation (NYSE:NVTA ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President and Chief Executive Officer Roxi Wen - Chief Financial Officer Conference Call Participants Gabriella Gabel - Morgan Stanley Dustin Scaringe – William Blair Jeffrey Cohen - Ladenburg Operator Hello, everybody, and welcome to the Invitae Fourth Quarter 2020 Financial Results Conference Call. My name is Sam, and I will be coordinating your call today.
It doesn't look good, but the company isn't doomed just yet.
The stock has been off to a red-hot start in 2023.
The company's $350 million question mark could overshadow recent progress.
Invitae Corporation (NYSE:NVTA ) 41st Annual JPMorgan Healthcare Conference January 11, 2023 12:00 PM ET Company Participants Kenneth Knight - Chief Executive Officer Dr. Bob Nussbaum - Chief Medical Officer Roxi Wen - Chief Financial Officer Dr. Valerie Montgomery Rice - President and CEO, Morehouse School of Medicine Conference Call Participants Julia Qin - JPMorgan Chase Julia Qin All right. Good morning, everyone.